BRPI0813625A2 - Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 - Google Patents
Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5Info
- Publication number
- BRPI0813625A2 BRPI0813625A2 BRPI0813625-4A2A BRPI0813625A BRPI0813625A2 BR PI0813625 A2 BRPI0813625 A2 BR PI0813625A2 BR PI0813625 A BRPI0813625 A BR PI0813625A BR PI0813625 A2 BRPI0813625 A2 BR PI0813625A2
- Authority
- BR
- Brazil
- Prior art keywords
- diseases mediated
- pyridozins
- alzk4
- alk5
- imidazo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113214 | 2007-07-26 | ||
| PCT/EP2008/059705 WO2009013335A1 (en) | 2007-07-26 | 2008-07-24 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813625A2 true BRPI0813625A2 (pt) | 2014-12-23 |
Family
ID=38694831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813625-4A2A BRPI0813625A2 (pt) | 2007-07-26 | 2008-07-24 | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8143253B2 (pt) |
| EP (1) | EP2183027B1 (pt) |
| JP (1) | JP5090528B2 (pt) |
| KR (1) | KR101150581B1 (pt) |
| CN (1) | CN101765442B (pt) |
| AT (1) | ATE522249T1 (pt) |
| AU (1) | AU2008280135B2 (pt) |
| BR (1) | BRPI0813625A2 (pt) |
| CA (1) | CA2694261A1 (pt) |
| CL (1) | CL2008002184A1 (pt) |
| CO (1) | CO6290714A2 (pt) |
| CR (1) | CR11207A (pt) |
| EA (1) | EA201000123A1 (pt) |
| EC (1) | ECSP109898A (pt) |
| ES (1) | ES2375425T3 (pt) |
| MA (1) | MA31571B1 (pt) |
| PE (1) | PE20090506A1 (pt) |
| SV (1) | SV2010003463A (pt) |
| TN (1) | TN2010000040A1 (pt) |
| TW (1) | TW200911814A (pt) |
| WO (1) | WO2009013335A1 (pt) |
| ZA (1) | ZA201000079B (pt) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006017858D1 (de) * | 2005-08-30 | 2010-12-09 | Sumitomo Chemical Co | Verfahren zur herstellung einer sulfonylchloridverbindung |
| US20110105457A1 (en) * | 2008-04-18 | 2011-05-05 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on pi3k |
| US8987273B2 (en) * | 2010-07-28 | 2015-03-24 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-B]pyridazines |
| US8754114B2 (en) * | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US9040691B2 (en) * | 2011-07-01 | 2015-05-26 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors |
| PE20221914A1 (es) | 2011-12-28 | 2022-12-23 | Global Blood Therapeutics Inc | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido |
| EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| KR102092988B1 (ko) | 2012-09-28 | 2020-03-25 | 벤더르빌트 유니버시티 | 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들 |
| WO2014055955A1 (en) | 2012-10-05 | 2014-04-10 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| MY191087A (en) | 2013-03-15 | 2022-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237348C1 (en) | 2013-03-15 | 2019-02-07 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20160078A1 (es) | 2013-03-15 | 2016-03-02 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
| AU2014253798C1 (en) | 2013-04-19 | 2019-02-07 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CN105431147A (zh) | 2014-02-07 | 2016-03-23 | 全球血液疗法股份有限公司 | 2-羟基-6-((2-(1-异丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)苯甲醛的游离碱的结晶多晶型物 |
| US10233170B2 (en) | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
| TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| CN106478516A (zh) * | 2016-08-31 | 2017-03-08 | 安徽省鸿鑫生物科技有限公司 | 一种5‑氯哒嗪酮的合成方法 |
| CN106478517A (zh) * | 2016-08-31 | 2017-03-08 | 安徽省鸿鑫生物科技有限公司 | 一种2‑甲基5‑氯哒嗪酮的合成方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107805252A (zh) * | 2017-10-25 | 2018-03-16 | 上海道亦化工科技有限公司 | 一种基于咪唑并哒嗪的有机电致发光化合物及其用途和有机电致发光器件 |
| WO2019105886A1 (en) | 2017-12-02 | 2019-06-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| US10745400B2 (en) | 2018-03-14 | 2020-08-18 | Vanderbuilt University | Inhibition of BMP signaling, compounds, compositions and uses thereof |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| EP3788047B1 (en) | 2018-05-04 | 2024-09-04 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| CN114787160A (zh) | 2018-12-20 | 2022-07-22 | 因赛特公司 | 作为活化素受体样激酶-2的抑制剂的咪唑并哒嗪和咪唑并吡啶化合物 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| CA3157428A1 (en) | 2019-12-19 | 2021-06-24 | Universite De Strasbourg | Sigma-1 receptor ligands and uses thereof |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11840546B2 (en) * | 2020-06-12 | 2023-12-12 | Incyte Corporation | Imidazopyridazine compounds and uses thereof |
| WO2022013311A1 (en) | 2020-07-15 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| KR20230051500A (ko) | 2020-07-15 | 2023-04-18 | 키에시 파르마슈티시 엣스. 피. 에이. | Alk5 억제제로서 피리다진일 아미노 유도체 |
| BR112023000592A2 (pt) | 2020-07-15 | 2023-01-31 | Chiesi Farm Spa | Derivados de pirido oxazina amino como inibidores de alk5 |
| WO2022136221A1 (en) | 2020-12-23 | 2022-06-30 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| WO2023046698A1 (en) | 2021-09-21 | 2023-03-30 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ244598A3 (cs) | 1996-02-07 | 1998-10-14 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidiny jako antagonisty CRF receptoru |
| KR20010087738A (ko) * | 1998-10-21 | 2001-09-21 | 다케다 야쿠힌 고교 가부시키가이샤 | 축합 피리다진 유도체, 이의 제조 방법 및 용도 |
| GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| EP1599482A4 (en) | 2003-02-28 | 2008-10-01 | Teijin Pharma Ltd | PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES |
| US7759349B2 (en) * | 2003-12-31 | 2010-07-20 | Schering-Plough Animal Health Corporation | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
| US8030327B2 (en) * | 2004-11-08 | 2011-10-04 | Mds K.K. | Fused imidazole derivative |
| DK1869049T3 (da) | 2005-03-21 | 2009-05-18 | Lilly Co Eli | Imidazopyridazinforbindelser |
| EP1879896A1 (en) | 2005-04-05 | 2008-01-23 | Eli Lilly And Company | Imidazopyridazine compounds |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2008094556A2 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
-
2008
- 2008-07-24 PE PE2008001257A patent/PE20090506A1/es not_active Application Discontinuation
- 2008-07-24 US US12/670,188 patent/US8143253B2/en not_active Expired - Fee Related
- 2008-07-24 AT AT08775322T patent/ATE522249T1/de not_active IP Right Cessation
- 2008-07-24 EA EA201000123A patent/EA201000123A1/ru unknown
- 2008-07-24 EP EP08775322A patent/EP2183027B1/en active Active
- 2008-07-24 AU AU2008280135A patent/AU2008280135B2/en not_active Ceased
- 2008-07-24 CN CN200880100481.6A patent/CN101765442B/zh not_active Expired - Fee Related
- 2008-07-24 WO PCT/EP2008/059705 patent/WO2009013335A1/en active Application Filing
- 2008-07-24 KR KR1020107001656A patent/KR101150581B1/ko not_active IP Right Cessation
- 2008-07-24 JP JP2010517403A patent/JP5090528B2/ja not_active Expired - Fee Related
- 2008-07-24 ES ES08775322T patent/ES2375425T3/es active Active
- 2008-07-24 CA CA2694261A patent/CA2694261A1/en not_active Abandoned
- 2008-07-24 BR BRPI0813625-4A2A patent/BRPI0813625A2/pt not_active IP Right Cessation
- 2008-07-25 CL CL2008002184A patent/CL2008002184A1/es unknown
- 2008-07-25 TW TW097128501A patent/TW200911814A/zh unknown
-
2010
- 2010-01-05 ZA ZA201000079A patent/ZA201000079B/xx unknown
- 2010-01-08 CR CR11207A patent/CR11207A/es not_active Application Discontinuation
- 2010-01-22 TN TNP2010000040A patent/TN2010000040A1/fr unknown
- 2010-01-22 MA MA32544A patent/MA31571B1/fr unknown
- 2010-01-25 EC EC2010009898A patent/ECSP109898A/es unknown
- 2010-01-25 CO CO10007036A patent/CO6290714A2/es not_active Application Discontinuation
- 2010-01-26 SV SV2010003463A patent/SV2010003463A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US8143253B2 (en) | 2012-03-27 |
| CN101765442B (zh) | 2014-09-17 |
| SV2010003463A (es) | 2010-04-13 |
| CA2694261A1 (en) | 2009-01-29 |
| AU2008280135A1 (en) | 2009-01-29 |
| US20100204235A1 (en) | 2010-08-12 |
| EP2183027B1 (en) | 2011-08-31 |
| ZA201000079B (en) | 2010-09-29 |
| TN2010000040A1 (en) | 2011-09-26 |
| JP2010534633A (ja) | 2010-11-11 |
| KR101150581B1 (ko) | 2012-06-11 |
| CN101765442A (zh) | 2010-06-30 |
| JP5090528B2 (ja) | 2012-12-05 |
| EA201000123A1 (ru) | 2010-08-30 |
| ATE522249T1 (de) | 2011-09-15 |
| ES2375425T3 (es) | 2012-02-29 |
| CL2008002184A1 (es) | 2009-05-08 |
| CR11207A (es) | 2010-02-12 |
| AU2008280135B2 (en) | 2012-02-23 |
| PE20090506A1 (es) | 2009-05-28 |
| ECSP109898A (es) | 2010-02-26 |
| TW200911814A (en) | 2009-03-16 |
| CO6290714A2 (es) | 2011-06-20 |
| EP2183027A1 (en) | 2010-05-12 |
| MA31571B1 (fr) | 2010-08-02 |
| WO2009013335A1 (en) | 2009-01-29 |
| KR20100034028A (ko) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0813625A2 (pt) | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 | |
| TN2010000167A1 (en) | Organic compounds | |
| TN2010000305A1 (en) | Pyrrolopyrimidines and pyrrolopyridines | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
| GB0305152D0 (en) | Organic compounds | |
| EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
| MY150059A (en) | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| WO2018038988A3 (en) | Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them | |
| WO2007068473A3 (en) | Organic compounds | |
| WO2012078674A8 (en) | Substituted indole/indazole-pyrimidinyl compounds | |
| UA100390C2 (en) | Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |